Skip to content

Study · Animal study (in vivo) · mouse · 1999

1 result

Neuroprotection of the developing brain by systemic administration of vasoactive intestinal peptide derivatives.

Gressens P, Besse L, Robberecht P, Gozes I, Fridkin M, Evrard P

The Journal of pharmacology and experimental therapeutics1 Mar 1999Cited by 37 (Europe PMC)

PMID10027860 (opens in a new tab)DOI10.1016/s0022-3565(24)38075-9 (opens in a new tab)PepBankPUB-10027860
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In newborn mice with ibotenate-induced white matter lesions, intraperitoneal VIP given together with ibotenate was not protective.

    In plain wordsIn newborn mice, VIP injected into the belly together with ibotenate did not protect the brain white matter.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeWhite matter protection by i.p. VIP given with ibotenate
    Study

    mousen: not reported in source

    Newborn mice with ibotenate-induced white matter cysts
    Comparator
    Ibotenate alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    By comparison, i.p. coadministration of VIP and ibotenate was not protective against the excitotoxic insult.
    1 context sentence
    Summary · context
    The goal of the present study was to assess the protective properties of systemically injected VIP analogs against ibotenate-induced excitotoxic white matter lesions in newborn mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.